Blueprint Medicines — Investor Presentation (September 2020)
18 slides from Blueprint Medicines's investor presentation, Sep 22, 2020
Slide 1: Topline data for EXPLORER and PATHFINDER clinical trials in advanced systemic mastocytosis
© 2020 Blueprint Medicines Corporation R.S., living with systemic mastocytosis Topline data for EXPLORER and PATHFINDER clinical trials in advanced systemic mastocytosis SEPTEMBER 22, 2020
Slide 2: Forward-looking statements
Forward-looking statements 2 This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “aim,” “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “
Slide 3: Blueprint Medicines call participants
Blueprint Medicines call participants Introduction Kristin Hodous, Sr. Manager, Investor Relations Opening remarks Jeff Albers, Chief Executive Officer Review of topline EXPLORER and PATHFINDER data Andy Boral, MD, PhD, Chief Medical Officer Opportunity to deliver therapeutic value to patients with
Slide 4: Top-line advanced SM data adds to increasing portfolio strength
Top-line advanced SM data adds to increasing portfolio strength 1. Full prescribing information is available at www.GAVRETO.com. advSM, advanced systemic mastocytosis; ESMO, European Society of Medical Oncology; FDA, U.S. Food and Drug Administration; GIST, gastrointestinal stromal tumors; ISM, indo
Slide 5: Top-line data
Top-line EXPLORER and PATHFINDER data Andy Boral, MD, PhD, Chief Medical Officer
Slide 6: Driven by KIT D816V, systemic mastocytosis is characterized by debilitating symptoms and organ damage
Driven by KIT D816V, systemic mastocytosis is characterized by severely debilitating symptoms and organ damage Mild symptoms Non-Advanced SM Severe symptoms Indolent SM (ISM) • Some progression to advanced disease (4%)2 • Long-term morbidity, including life- threatening anaphylaxis, frequent GI upse
Slide 7: Comprehensive development program designed to support avapritinib registration in advanced SM
Comprehensive development program designed to support avapritinib registration in advanced systemic mastocytosis 7 mIWG, modified International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) response criteria. QD, once
Slide 8: Planned avapritinib sNDA submission for advanced SM to include pooled data
Planned avapritinib sNDA submission for advanced SM to include pooled data from the EXPLORER and PATHFINDER trials All topline data in this presentation are as of a data cutoff of May 27, 2020 for EXPLORER and a data cutoff of June 23, 2020 for PATHFINDER, with response assessments per central revie
Slide 9: Consistently high ORRs and prolonged duration of response across trials
Consistently high ORRs and prolonged duration of response across trials CR, complete remission; CRh, CR with partial hematologic recovery; CI, clinical improvement; mDOR, median duration of response; mOS, median overall survival; NE, not estimable; ORR, overall response rate; PR, partial remission.
Slide 10: Response kinetics are similar, with deepening responses over time
EXPLORER and PATHFINDER response kinetics are similar, with deepening responses over time with longer-term follow up PD, progressive disease; SD, stable disease. 10 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 0 10 20 30 40 50 60 70 80 90 100 P a t i e n t s ( % ) NE PD SD CI PR CRh CR 32 n =
Slide 11: Consistent impact on objective measures of mast cell burden across trials
Consistent impact on objective measures of mast cell burden across trials 11 -100 -80 -60 -40 -20 0 20 M a x i m u m P e r c e n t C h a n g e f r o m B a s e l i n e BLU-285-2202 BLU-285-2101 Study SERUM TRYPTASE -100 -80 -60 -40 -20 0 20 40 60 M a x i m u m P e r c e n t C h a n g e f r o m B a s
Slide 12: Avapritinib demonstrated improved tolerability at 200 mg QD
Avapritinib demonstrated improved tolerability at 200 mg QD 12 Treatment Emergent AEs ≥ 20%, All Grades* 200 mg n=81 (%) All doses N=148 (%) Peripheral Edema 39 ( 48.1) 65 ( 43.9) Periorbital Edema 32 ( 39.5) 81 ( 54.7) Thrombocytopenia 28 ( 34.6) 55 ( 37.2) Anemia 26 ( 32.1) 65 ( 43.9) Diarrhea 23
Slide 13: Summary of top-line trial results
Summary of top-line EXPLORER and PATHFINDER trial results 13 Consistently high IWG response rates across trials and at the proposed labeled 200 mg QD dose, with prolonged overall survival in EXPLORER Avapritinib was generally well-tolerated, with improved safety at 200 mg QD and with platelet manage
Slide 14: Opportunity to deliver therapeutic value to patients with SM
Opportunity to deliver therapeutic value to patients with SM Christy Rossi, Chief Commercial Officer
Slide 15: Systemic mastocytosis is one disease driven by KIT D816V
Systemic mastocytosis is one disease driven by KIT D816V 15 Advanced SM Non-advanced SM (Indolent and smoldering) Requirement for life-long chronic treatment Debilitating symptoms Significant organ damage Importance of time to response ~75,000 patients in major markets Patient numbers in major marke
Slide 16: Significant initial target patient population with additional growth potential
Significant initial target patient population with additional growth potential Major markets include US, EU5 and Japan. 1. Cohen S et al Br J Haematol (2014) 166(4):521-8 and World Bank Population estimates. 16 ~75,000 Patients in major markets ~1/3 Diagnosed Initial opportunity Growth opportunity E
Slide 17: Avapritinib is the only clinically validated, highly potent inhibitor of KIT D816V
Avapritinib is the only clinically validated, highly potent inhibitor of KIT D816V, the genetic driver of SM 1. Topline EXPLORER and PATHFINDER data reported in September 2020. 2. Data reported at AAAAI Annual Meeting in March 2020. Data cutoff: December 27, 2019. 17 REDUCE MAST CELL BURDEN IMPROVE
Slide 18: Thank you
Thank you Blueprint Medicines, AYVAKIT, GAVRETO and associated logos are trademarks of Blueprint Medicines Corporation.
Blueprint Medicines — Investor Presentation (September 2020) on 6ix